Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

HRSA Unveils New 340B Flexibilities During COVID-19 Crisis

By Brenda Maloney Shafer & Richard Davis on March 23, 2020
Email this postTweet this postLike this postShare this post on LinkedIn

As the COVID-19 crisis continues to unfold, the Health Resources & Services Administration Office of Pharmacy Affairs (HRSA OPA) has taken unprecedented steps to provide 340B Program participants with additional flexibility to help meet surging patient demand. At the highest level, HRSA OPA acknowledges that “this public health emergency may warrant additional flexibilities, especially to affected 340B covered entities.”

More specifically, HRSA OPA has taken the following steps and provided the following guidance to assist 340B Program participants treating a surge in patients during this crisis:

  • Relaxing patient recordkeeping requirements necessary to determine patient eligibility. HRSA OPA has stated that for the time being “an abbreviated health record may be adequate for purposes of the 340B Program. The record should identify the patient, record the medical evaluation (including any testing, diagnosis or clinical impressions) and the treatment provided or prescribed. For purposes of 340B Program eligibility, the record may be a single form or note page.”
  • Confirming that volunteer health professionals providing health care on behalf of the covered entity may be considered eligible providers for purposes of the 340B Program. Emergency documentation should be generated to make the relationship between the provider and the covered entity clear and to make clear the covered entity’s responsibility for providing care. This documentation should recognize the emergency nature of the situation, the name and address of the volunteer, and his/her relationship to the clinic, and should be kept on file by the covered entity.
  • Indicating that “case-by-case” exceptions may be granted for covered entities seeking to expand their services to new sites outside of the normal enrollment process.
  • Confirming that as of now, HRSA OPA is unable to waive the 340B statutory requirements related to the eligible patient definition and GPO prohibition.
  • Clarifying that telehealth encounters remain eligible for 340B Program purposes. HRSA OPA recommends that covered entities outline the use of these modalities in their policies and procedures, and continue to ensure auditable records are maintained for each eligible patient dispensed a 340B drug.
  • Moving toward conducting 340B Program covered entity audits remotely (virtually) for the next several months while HRSA OPA monitors and assesses the impact on the covered entities.

HRSA OPA’s unprecedented actions will likely be quickly evolving and subject to change. 340B Program participants should carefully evaluate how these new flexibilities may enable them to expand existing services to rise to the unique challenge of this crisis.

Photo of Brenda Maloney Shafer Brenda Maloney Shafer

Brenda is a member of Quarles & Brady’s Health Law Practice Group. Her practice focuses primarily in health law and, in particular, health care regulatory and transactional work. Along with her law degree, she holds a Master’s of Law in Health Law. A…

Brenda is a member of Quarles & Brady’s Health Law Practice Group. Her practice focuses primarily in health law and, in particular, health care regulatory and transactional work. Along with her law degree, she holds a Master’s of Law in Health Law. A particular area of focus is counseling clients regarding compliance with the 340B Drug Pricing Program.

Read more about Brenda Maloney ShaferEmailBrenda Maloney's Linkedin Profile
Show more Show less
Photo of Richard Davis Richard Davis

Richie has extensive experience with the 340B Program and has worked with both contract pharmacies and covered entities to develop and optimize their program participation. His practice also focuses on a wide variety of pharmacy regulatory issues, including controlled substances and state licensure…

Richie has extensive experience with the 340B Program and has worked with both contract pharmacies and covered entities to develop and optimize their program participation. His practice also focuses on a wide variety of pharmacy regulatory issues, including controlled substances and state licensure compliance.

Read more about Richard DavisEmailRichard's Linkedin Profile
Show more Show less
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    To Be or Not to 340B Blog
  • Organization:
    Quarles & Brady LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo